NCT03730584View on ClinicalTrials.gov

Evaluation of the Efficacy of ROPIVACAINE in Children and Young Adults With Hereditary Epidermolysis Bullosa

NACompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

February 27, 2017

Primary Completion Date

November 28, 2019

Study Completion Date

November 28, 2019

Conditions
Epidermolysis Bullosa
Interventions
DRUG

Ropivacaine

"Ampoules of ROPIVACAINE 2mg / ml will be used by local cutaneous application in soft application with device of hand shower on the painful wounds without exceeding the dose of 1mg / kg per bath."

BIOLOGICAL

Blood test

Blood test during the first bath with Ropivacaine for Titration of Ropivacaine

Trial Locations (1)

75015

Hôpital Necker Enfants Malades, Paris

All Listed Sponsors
lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT03730584 - Evaluation of the Efficacy of ROPIVACAINE in Children and Young Adults With Hereditary Epidermolysis Bullosa | Biotech Hunter | Biotech Hunter